Pipeline
BX-101 doses first patient in Phase 1 solid tumour study
The KEYSTONE-1 dose-escalation study is evaluating Baxtra's oral KRAS G12D degrader in patients with advanced pancreatic, colorectal and lung cancers at four sites across Florida, Texas and Georgia.
Media enquiriesRegulatory
Lumavue™ perfusion imaging system receives FDA 510(k) clearance
Baxtra's first cleared product provides quantitative, real-time assessment of tissue perfusion during general, colorectal and reconstructive surgery. Commercial availability begins in Florida in Q4 2026.
Media enquiriesCompany
Baxtra passes $90 million invested in research and development
Eighteen months after incorporation, cumulative R&D spend reached $90 million across the pharmaceutical and surgical technology divisions, funded entirely from the company's two private financing rounds.
Media enquiriesPipeline
BX-412 begins Phase 1 in elevated lipoprotein(a)
The ASCEND-1 study will assess safety, tolerability and Lp(a) lowering with Baxtra's liver-directed siRNA in adults with elevated lipoprotein(a).
Media enquiriesScience
Preclinical characterisation of BX-101 published
The Journal of Medicinal Chemistry paper describes selective degradation of mutant KRAS G12D with sparing of wild-type protein in patient-derived models.
Media enquiriesPipeline
First participant dosed in SUMMIT-1 with oral TL1A antagonist BX-204
The Phase 1 study focuses on fibrostenotic Crohn's disease, a population current biologics serve poorly.
Media enquiriesFinancing
Baxtra closes $175 million Series B
Proceeds will fund the four clinical programs through Phase 1 completion and take SealWeave into design verification. Total raised since founding is $265 million.
Media enquiriesPipeline
Two discovery programs discontinued at the candidate gate
A second-generation degrader series and an energy-based sealing device were stopped after failing pre-specified criteria. Rationale for both is published in our annual research summary.
Media enquiriesPeople
Baxtra reaches 200 employees across three Palm Beach County sites
Hiring in 2026 focused on clinical operations, regulatory affairs and device engineering.
Media enquiriesCompany
Palm Beach Gardens engineering and simulation facility opens
The 24,000 square foot site houses device engineering, rapid prototyping and a wet surgical simulation lab.
Media enquiriesCompany
Baxtra opens discovery laboratories in Jupiter, Florida
The Jupiter site houses chemistry, biology and biomarker analytics for all four drug programs.
Media enquiriesCompany
Baxtra founded in West Palm Beach
The company launched with a $90 million Series A and a mandate spanning pharmaceuticals, biotechnology and surgical technology.
Media enquiriesMedia contacts
For journalists on deadline: media@baxtra.com · +1 (561) 555-0188
Investor news
Financing history and information for prospective investors in a private company.
Investors